These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 25162361

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L.
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P, ALADIN study group.
    Lancet; 2013 Nov 02; 382(9903):1485-95. PubMed ID: 23972263
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
    Gillis JC, Noble S, Goa KL.
    Drugs; 1997 Apr 02; 53(4):681-99. PubMed ID: 9098666
    [Abstract] [Full Text] [Related]

  • 36. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
    Mystakidou K, Katsouda E, Tsilika E, Smyrniotis V, Vassiliou I, Tsiatas M, Vlahos L.
    Anticancer Res; 2006 Apr 02; 26(3B):2325-8. PubMed ID: 16821610
    [Abstract] [Full Text] [Related]

  • 37. Octreotide bolus injection and azygos blood flow in patients with cirrhosis: is the effect really predictable?
    Spahr L, Giostra E, Mentha G, Hadengue A.
    J Clin Gastroenterol; 2010 Oct 02; 44(9):e206-9. PubMed ID: 19996986
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.
    Chieffo C, Cook D, Xiang Q, Frohman LA.
    J Clin Endocrinol Metab; 2013 Oct 02; 98(10):4047-54. PubMed ID: 23969184
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.